Medical treatment of Cushing's disease: Overview and recent findings

International Journal of General Medicine

Volumn 2, Issue , 2009, Pages 209-217

  Praw, Stephanie Smooke ^a   Heaney, Anthony P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

11 hydroxysteroid dehydrogenase inhibitors; Cushing's disease; Dopamine agonists; Pasireotide; PPAR ; Treatment

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 CHLORO 2 METHYL N [4 [2 (4 METHYL 1 PIPERAZINYL) 2 OXOETHYL] 2 THIAZOLYL]BENZENESULFONAMIDE; AMINOGLUTETHIMIDE; ANGIOPEPTIN; BROMOCRIPTINE; BVT 3498; CABERGOLINE; DEXAMETHASONE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; ETOMIDATE; KETOCONAZOLE; LISURIDE; METYRAPONE; MIFEPRISTONE; MITOTANE; OCTREOTIDE; PASIREOTIDE; PERGOLIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOIC ACID; ROSIGLITAZONE; SOMATOSTATIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACNE; ACROMEGALY; ADRENALECTOMY; ALOPECIA; ARTHRALGIA; ASTHENIA; ATAXIA; CARCINOID; CLINICAL TRIAL; CORTICOTROPIN RELEASE; CUSHING DISEASE; CYTOTOXICITY; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG MECHANISM; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; EDEMA; FLUSHING; GASTROINTESTINAL TOXICITY; GYNECOMASTIA; HEADACHE; HIRSUTISM; HUMAN; HYPERCALCEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPOTENSION; KIDNEY FAILURE; LIVER TOXICITY; NAUSEA; NELSON SYNDROME; PANCREATITIS; PROLACTINOMA; RADIOTHERAPY; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; STEROIDOGENESIS; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 77953412395     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Biller BMK, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: A consensus statement. J Clin Endocrinol Metab. 2008;93:2454-2642.
2. Arnaldi G, Mancini T, Polenta B, Boscaro M. Cardiovascular risk in Cushing's syndrome. Pituitary. 2004;7(4):253-256.
3. Pivonello R, Faggiano A, Lombardi G, Colao A. The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin North Am. 2005;34(2):327-339.
4. Molitch ME. Medical management of prolactin secreting pituitary adenomas. Pituitary. 2002;5(2):55-65.
5. Melmed S. Update in pituitary disease. J Clin Endocrinol Metab. 2008;93(2):331-338.
6. Prevedello DM, Pouratian N, Sherman J, et al. Management of Cushing's disease: outcome in patients with microadenoma detected on pituitary magnetic resonance imaging. J Neurosurg. 2008;109(4):751-759.
7. Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol. 2005;63(5): 549-559.
8. Cannavò S, Almoto B, Dall'Asta C, et al. Long-term results of treatment in patients with ACTH-secreting pituitary macroadenomas. Eur J Endocrinol. 2003;149:195-200.
9. Brada M, Rajan B, Traish D, et al. The long-term eff icacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol. 1993;38:571-578.
10. llolio B, Schulte HM, Kaulen D, Reincke M, Jaursch-Hancke C, Winkelmann W. Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in Cushing's syndrome. J Mol Med. 1988; 66:1432-1440.
11. Bertagna X, Bertagna C, Laudat MH, Husson JM, Girard F, Luton JP. Pituitary-adrenal response to the antiglucocorticoid action of RU-486 in Cushing's syndrome. J Clin Endocrinol Metab. 1986;63:639-643.
12. Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU-486). J Clin Endocrinol Metab. 2001;86:3568-3573.
13. Castinetti F, Fassnacht M, Johanssen S, et al. Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol. 2009;160(6): 1003-1010.
14. Heaney AP. Novel medical approaches for the treatment of Cushing's disease. J Endocrinol Invest. 2004;27:591-595.
15. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347:645-660.
16. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferators signaling pathways through heterodimer formation of their receptors. Nature. 1992;358:771-774.
17. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998;47:507-514.
18. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45:1661-1669.
19. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
20. Heaney AP, Fernando M, Yong W, Melmed S. Functional PPAR-gamma receptor represents a novel therapeutic target in Cushing's disease. Nat Med. 2002;11:1281-1287.
21. Heaney AP, Fernando M, Melmed S. PPAR-gamma receptor ligands: A novel therapy for pituitary tumors. J Clin Invest. 2003;111:1381-1388.
22. Gruszka A, Kunert-Radek J, Pawlikowski M. Rosiglitazone PPAR-gamma ligand decreases the viability of rat prolactinsecreting pituitary tumor cells in vitro. Neuro Endocrinol Lett. 2005;26:51-54.
23. Bogazzi F, Ultimieri F, Raggi F, et al. PPAR-gamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. Eur J Endocrinol. 2004;150:863-875.
24. Hull SSA, Sheridan B, Atkinson AB. Pre-operative medical therapy with rosiglitazone in two patients with newly diagnosed pituitary-dependent Cushing's syndrome. Clin Endocrinol. 2004;62:258-262.
25. Ambrosi B, Dall'Asta C, Cannavo S, et al. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol. 2004;151:173-178.
26. Pecori Geraldi F, Scaroni G, Arvat E, et al. Effect of protracted treatment with rosiglitazone, a PPAR-gamma agonist, in patients with Cushing's disease. Clin Endocrinol. 2006;64:219-224.
27. Morcos M, Fohr B, Tafel J, et al. Long-term treatment of central Cushing's Syndrome with rosiglitazone. Exp Clin Endocrinol Diabetes. 2007;115:292-297.
28. Kurie JM. The biologic basis for the use of retinoids in cancer prevention and treatment. Curr Opin Oncol. 1999;11:497-502.
29. Pereda-Paez M, Kovalovsky D, Hopfner U, et al. Retinoic acid prevents experimental Cushing syndrome. J Clin Invest. 2001;108: 1123-1131.
30. Castillo V, Giacomini D, Paez-Pareda M, et al. Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology. 2006;147:4438-4444.
31. Aboulafia DM, Norris D, Henry D, et al. 9-cis-retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma: results of a phase 2 multicenter clinical trial. Arch Dermatol. 2003;139:178-186.
32. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94: 1509-1517.
33. Tyrrell JB, Lorenzi M, Gerich JE, Forsham PH. Inhibition by somatostatin of ACTH secretion in Nelson's syndrome. J Clin Endocrinol Metab. 1975;6:1125-1127.
34. Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibanski A. Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab. 1995;80:1386-1392.
35. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24:28-47.
36. Shimon I, Taylor JE, Dong JZ, et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures. J Clin Invest. 1997;4:789-798.
37. Bruns C, Lewis I, Briner U, Meno-Tetang G, Wechbecker G. SOM230: A novel somatostatin peptidomimetic with broad somatostatin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;5:707-716.
38. Shimon I. Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogues. Endocrine. 2003;2:265-270.
39. Strowski MZ, Dashkevicz MP, Parmar RM, et al. Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticoptropin secretion from AtT-20 cells. Neuroendocrinology. 2002;75:339-346.
40. Hofland LJ, van der Hoek J, Feelders R, et al. The multiligand somatostatin analog SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor subtype 5. Eur J Endocrinol. 2005;152:645-654.
41. Boscaro M, Ludlam WH, Atkinson B, et al. Treatment of pituitarydependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009;94(1):115-122.
42. Ferone D, Pivonello R, Resmini E, et al. Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas. Eur J Endocrinol. 2007;156:S37-S43.
43. Pivonello R, Ferone D, de Herder WW, et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab. 2004;89:2452-2462.
44. Pivenello R, De Martino MC, Cappabianca P, et al. The medical treatment of Cushing's disease: Effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab. 2009;94:223-230.
45. Pivonello R, Ferone D, de Herder WW, et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab. 2004;89:2452-2462.
46. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356:29-38.
47. Cheung D, Heaney A. Dopamine agonists and valvular heart disease. Curr Opin Endocrinol Diab Obes. 2009;16:316-320.
48. De Bruin C, Periera AM, Feelders RA, et al. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab. 2009;94:1118-1124.
49. Seckl JR, Walker BR. 11 beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory. Trends Endocrinol Metab. 2004;15:418-424.
50. Wamil M, Seckl JR. Inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discov Today. 2007;12:504-520.
51. Sandeep TC, Andrew R, Homer NZ, Andrews RC, Smith K, Walker BR. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-dehydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes. 2005;54:872-879.